Peptides

A novel peptide that uniquely affects the effector and regulatory arms of immune responses has potential for treating eosinophilic esophagitis and other allergic diseases, according to a press release from Revolo Biotherapeutics.

An immunotherapy comprising seven synthetic peptides may provide a safe and durable alternative to immunotherapies based on whole peanuts, according to a study published in Allergy.

Patients experienced a rapid reduction in allergic inflammation caused by an intradermal grass pollen challenge after one dose of a first-in-class peptide, according to a press release from Revolo Biotherapeutics.

Healthy volunteers taking a first-in-class peptide designed for treating eosinophilic esophagitis did not experience any clinically significant adverse safety findings at any of three evaluated doses, according to a press release.

Emerging data suggest immunotherapies and novel peptides that target gut inflammation could serve as complementary agents to available diabetes drugs to more effectively target cardiometabolic diseases, according to a speaker.

SAN FRANCISCO — More patients with dry age-related macular degeneration treated with risuteganib, a small synthetic peptide that regulates select integrin functions involved in the pathogenesis of the disease, experienced an eight or more letter gain in best corrected visual acuity 12 weeks after treatment compared with a sham group, according to a speaker here.